FY2027 EPS Estimates for Prothena Reduced by HC Wainwright

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Investment analysts at HC Wainwright dropped their FY2027 EPS estimates for Prothena in a research note issued to investors on Tuesday, May 27th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of ($5.44) for the year, down from their previous estimate of ($4.70). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena's FY2028 earnings at ($2.73) EPS and FY2029 earnings at ($3.56) EPS.

Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. During the same quarter in the prior year, the firm earned ($1.34) EPS. The firm's revenue was up 5500.0% compared to the same quarter last year.

A number of other brokerages also recently issued reports on PRTA. Cantor Fitzgerald downgraded shares of Prothena from an "overweight" rating to a "neutral" rating in a research note on Tuesday. Oppenheimer downgraded shares of Prothena from an "outperform" rating to a "market perform" rating in a research note on Tuesday. Wall Street Zen upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Piper Sandler reduced their price objective on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday. Finally, Bank of America restated an "underperform" rating on shares of Prothena in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Prothena has an average rating of "Hold" and an average target price of $31.50.

Prothena Stock Down 2.3%

Prothena stock traded down $0.11 during trading on Thursday, reaching $4.59. The stock had a trading volume of 1,963,387 shares, compared to its average volume of 686,990. Prothena has a 52-week low of $4.32 and a 52-week high of $25.42. The business has a 50 day moving average price of $8.88 and a 200 day moving average price of $12.48. The stock has a market cap of $247.07 million, a PE ratio of -2.00 and a beta of 0.11.

Institutional Trading of Prothena

Several institutional investors have recently modified their holdings of PRTA. Virtus ETF Advisers LLC increased its holdings in shares of Prothena by 19.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 833 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Prothena by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 1,065 shares during the period. Rhumbline Advisers increased its holdings in shares of Prothena by 1.8% in the 4th quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock valued at $930,000 after acquiring an additional 1,175 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Prothena by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company's stock valued at $381,000 after acquiring an additional 1,551 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Prothena by 4.0% in the 4th quarter. Invesco Ltd. now owns 42,846 shares of the biotechnology company's stock valued at $593,000 after acquiring an additional 1,632 shares during the period. Hedge funds and other institutional investors own 97.08% of the company's stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.